BioNexus Gene Lab Corp. and ML Tech Forge Partnership for Enhanced Ethereum Treasury Strategy
KUALA LUMPUR, Malaysia – March 8, 2025 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company focused on innovation in the digital and healthcare sectors, has revealed a strategic partnership with ML Tech. The collaboration aims to optimize BGLC’s Ethereum-based growth strategies.
ML Tech, based in Miami, Florida, is an AI-driven wealth management platform specializing in digital assets regulated by the National Futures Association (NFA). This partnership follows BGLC’s announced Ethereum treasury strategy, indicating the company’s commitment to technological and financial advancements.
BGLC plans to utilize ML Tech’s advanced digital asset trading infrastructure to cultivate its Ethereum holdings. ML Tech’s institutional-grade trading strategies and sophisticated quantitative models will provide BioNexus with tailored investment solutions, engineered to maximize returns while adhering to stringent risk management protocols.
“We are excited to collaborate with BioNexus Gene Lab Corp. to bring our innovative Ethereum yield strategies to their treasury operations,” said Leo Mindyuk, CEO and CIO of ML Tech.
“Our quantitative trading expertise and non-custodial execution model will empower BGLC to optimize its Ethereum holdings while preserving full transparency and security.”
The partnership aligns with BGLC’s wider strategic vision of integrating blockchain technologies into its financial operations. By leveraging ML Tech’s AI-driven platform, BGLC aims to grow its Ethereum reserves while maintaining liquidity and control. The collaboration also suggests possibilities for novel financial structures in the open market.
“The decision to implement an Ethereum treasury strategy underscores our commitment to improving shareholder value through innovation in the digital, AI driven future,” stated Sam Tan, CEO of BioNexus Gene Lab Corp.
“Partnering with ML Tech enables us to leverage our assets with an expert in the field to enhance the efficiency and performance of our treasury operations.”
BGLC selected ML Tech’s platform because of its suitability for institutional investors looking for low-correlation digital asset strategies. ML Tech has a strong track record in delta-neutral and market-neutral strategies. This enables it to offer investors sophisticated quantitative solutions to successfully navigate the intricacies of digital asset markets.
About BioNexus Gene Lab Corp:
BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a tech company dedicated to pioneering advancements in the digital and healthcare space. By focusing on integrating innovative technologies, BGLC tries to ensure sustainable growth and value for its shareholders. More information can be found at https://www.bionexusgenelab.com/ethstrategy.
About ML Tech:
ML Tech operates as an institutional digital asset platform offering optimized blended portfolios and bespoke trading strategies. Via its marketplace, investors gain access to real-time NAV, portfolio insights, and a spectrum of market-neutral and smart beta strategies. For more information, visit www.mltech.ai or contact allocators@mltech.ai.
For investor inquiries or media requests:
IR@BIONEXUSGENELAB.COM
Forward-Looking Statements:
This press release includes forward-looking statements that involve risks and uncertainties. Actual outcomes may differ due to a variety of reasons, including market conditions and regulatory developments. BioNexus Gene Lab Corp. is not obligated to update forward-looking statements, except as mandated by law.
